TNFR2 - Target for therapeutics against neurodegenerative diseases?

Advances in Experimental Medicine and Biology

Volumn 691, Issue , 2011, Pages 567-573

  Nijholt, Ingrid M ^a,b   Granic, Ivica ^a   Luiten, Paul G M ^a   Eisel, Ulrich L M ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; CYTOKINE; CYTOKINE RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; INTERLEUKIN 2; INTERLEUKIN 6; MEVINOLIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; SMALL CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; NEUROPROTECTIVE AGENT; TUMOR NECROSIS FACTOR ALPHA;

ACTION POTENTIAL; ALZHEIMER DISEASE; BRAIN ISCHEMIA; CELL SURVIVAL; CONCENTRATION RESPONSE; CONFERENCE PAPER; DEGENERATIVE DISEASE; ENZYME ACTIVATION; ENZYME KINETICS; ENZYME PHOSPHORYLATION; EXCITOTOXICITY; GENE EXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MULTIPLE SCLEROSIS; NERVE CELL EXCITABILITY; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PARKINSON DISEASE; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY MECHANISM; RETINA ISCHEMIA; SIGNAL TRANSDUCTION; STROKE; TREATMENT DURATION; ANIMAL; ARTICLE; BIOLOGICAL MODEL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MOUSE;

ANIMALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICE; MODELS, BIOLOGICAL; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SIGNAL TRANSDUCTION; SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79954446569     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-6612-4_59     Document Type: Conference Paper

References (26)

1. Dolga AM, Granic I, Blank T, Knaus HG, Spiess J, Luiten PG, Eisel UL, Nijholt IM (2008) TNF-alpha-mediates neuroprotection against glutamate-induced excitotoxicity via NF-kappaB-dependent up-regulation of K2.2 channels. J Neurochem 107(4):1158-1167
2. Dolga AM, Granic I, Nijholt IM, Nyakas C, van der Zee EA, Luiten PG, Eisel UL (2009) Pretreatment with Lovastatin prevents N-Methyl-D-Aspartate- induced neurodegeneration in the magnocellular nucleus basalis and behavioral dysfunction. J Alzheimers Dis 17:327-336
3. Dolga AM, Nijholt IM, Ostroveanu A, Ten Bosch Q, Luiten PG, Eisel UL (2008) Lovastatin induces neuroprotection through tumor necrosis factor receptor 2 signaling pathways. J Alzheimers Dis 13:111-122
4. Echternacher B, Falk W, Männel DN, Krammer PH (1990) Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J. Immunol 145: 3762-3766
5. Eisel ULM, Biber K, Luiten PGM. (2006) Life and death of nerve cells: Therapeutic cytokine signaling pathways. Curr Signal Transduct Ther 1:133-146
6. Fontaine V, Mohand-Said S, Hanoteau N, Fuchs C, Pfizenmaier K, Eisel U (2002) Neurodegenerative and neuroprotective effects of tumor necrosis factor (TNF) in retinal ischemia: Opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci 22, RC216:1-7
7. Kohler M, Hirschberg B, Bond CT, Kinzie JM, Marrion NV, Maylie J, Adelman JP (1996) Small-conductance, calcium-activated potassium channels from mammalian brain. Science 273:1709-1714
8. Kye MJ, Spiess J, Blank T (2007) Transcriptional regulation of intronic calcium-activated potassium channel SK2 promoters by nuclear factor-kappa B and glucocorticoids. Mol Cell Biochem 300(1-2):9-17
9. Lee AL, Dumas TC, Tarapore PE, Webster BR, Ho DY, Kaufer D, Sapolsky RM (2003) Potassium channel gene therapy can prevent neuron death resulting from necrotic and apoptotic insults. J Neurochem 86:1079-1088
10. Marchetti L, Klein M, Schlett K, Pfizenmaier K, Eisel UL (2004) TNF mediated neuroprotection against glutamate induced excitotoxicity is enhanced by NMDA receptor activation: Essential role of a TNF receptor 2 mediated PI3 kinase dependent NF-kB pathway. J Biol Chem 279:32869-32881
11. Mattson MP, Culmsee C, Yu Z, Camandola S (2000). Roles of nuclear factor kappaB in neuronal survival and plasticity. J Neurochem 74(2):443-456
12. Murthy SR, Teodorescu G, Nijholt IM, Dolga AM, Grissmer S, Spiess J, Blank T (2008) Identification and characterization of a novel, shorter isoform of the small conductance Ca2+ -activated K+ channel SK2. J Neurochem 106(6):2312-2321
13. Nuebel T, Schmitt S, Kaina B, Fritz G (2005) Lovastatin stimulates p75 TNF receptor (TNFR2) expression in primary human endothelial cells. Int J Mol Med 16:1139-1145
14. Rasmussen LM, Hansen PR, Nabipour MT, Olesen P, Kristiansen MT, Ledet T (2001) Diverse effects of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells. Biochem J 360(Pt 2):363-370
15. Sailer CA, Hu H, Kaufmann WA, Trieb M, Schwarzer C, Storm JF, Knaus HG (2002) Regional differences in distribution and functional expression of small-conductance Ca2+- activated K+ channels in rat brain. J Neurosci 22:9698-9707
16. Sailer CA, KaufmannWA, Marksteiner J, Knaus HG (2004) Comparative immunohistochemical distribution of three small-conductance Ca2+-activated potassium channel subunits, SK1, SK2, and SK3 in mouse brain. Mol Cell Neurosci 26:458-469
17. Santee SM, Owen-Schaub LB (1996) Human tumor necrosis factor receptor p75/80 (CD120b) gene structure and promoter characterization. J Biol Chem 271(35):21151-21159
18. Shmukler BE, Bond CT, Wilhelm S, Bruening-Wright A, Maylie J, Adelman JP, Alper SL (2001) Structure and complex transcription pattern of the mouse SK1 Kca channel gene, KCNN1. Biochim Biophys Acta 1518:36-46
19. Stepień K, Tomaszewski M, Czuczwar SJ (2005) Neuroprotective properties of statins. Pharmacol Rep 57:561-569
20. Stocker M (2004) Ca(2+)-activated K+ channels: Molecular determinants and function of the SK family. Nat Rev Neurosci 5:758-770
21. Strassmaier T, Bond CT, Sailer CA, Knaus HG, Maylie J, Adelman JP (2005) A novel isoform of SK2 assembles with other SK subunits in mouse brain. J Biol Chem 280:21231-21236
22. Tomita H, Shakkottai VG, Gutman GA, Sun G, Bunney WE, Cahalan MD, Chandy KG, Gargus JJ (2003) Novel truncated isoform of SK3 potassium channel is a potent dominantnegative regulator of SK currents: Implications in schizophrenia. Mol Psychiatry 8:524-535
23. van der Most PJ, Dolga AM, Nijholt IM, Luiten PG, Eisel UL (2009) Statins: Mechanisms of neuroprotection. Prog Neurobiol 88:64-75
24. Wajant H, Pfizenmaier K, Scheurich P (2003) Tumor necrosis factor signaling. Cell Death Differ 10(1):45-65
25. Zhu Y, Culmsee C, Klumpp S, Krieglstein J (2004). Neuroprotection by transforming growth factor-beta1 involves activation of nuclear factor-kappaB through phosphatidylinositol-3- OH kinase/Akt and mitogen-activated protein kinase-extracellular-signal regulated kinase1, 2 signaling pathways. Neuroscience 123(4):897-906
26. Wittekindt OH, Dreker T, Morris-Rosendahl DJ, Lehmann-Horn F, Grissmer S (2004). A novel non-neuronal hSK3 isoform with a dominant-negative effect on hSK3 currents. Cell Physiol Biochem 14(1-2):23-30